Global Diabetic Neuropathy Treatment Market Research Report Information By Disorder (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), By Treatment (Drugs, TENS, Others) and By End-User (Hospitals and Clinics, Retail Pharmacy, Online Pharmacy, Others) – Forecast to 2032

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER

6.1. Overview

6.2. Peripheral Neuropathy

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.3. Autonomic Neuropathy

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.4. Proximal Neuropathy

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

6.5. Focal Neuropathy

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT

7.1. Overview

7.2. Drugs

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.2.1. Analgesics

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.2.2. Antidepressant

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.2.3. Anticonvulsants

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.2.4. Others

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.3. Transcutaneous Electrical Nerve Stimulation (TENS)

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

7.4. Others

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER

8.1. Overview

8.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8.3. Retail Pharmacy

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8.4. Online Pharmacy

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

8.5. Others

Market Estimates & Forecast, by Region, 2023-2030

Market Estimates & Forecast, by Country, 2023-2030

9. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1.1. Overview

10.1.2. Competitive Analysis

11. COMPANY PROFILES

11.1. Abbott Laboratories

11.1.1. Company Overview

11.1.2. Disorder Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. F. Hoffmann-La Roche Ltd

11.2.1. Company Overview

11.2.2. Disorder Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Eli Lilly and Company

11.3.1. Company Overview

11.3.2. Disorder Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Johnson & Johnson

11.4.1. Company Overview

11.4.2. Disorder Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. GlaxoSmithKline Plc

11.5.1. Company Overview

11.5.2. Disorder Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. LUPIN LIMITED

11.6.1. Company Overview

11.6.2. Disorder Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Glenmark Pharmaceuticals Limited

11.7.1. Company Overview

11.7.2. Disorder Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Depomed, Inc

11.8.1. Company Overview

11.8.2. Disorder Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Astellas Pharma Inc

11.9.1. Company Overview

11.9.2. Disorder Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Pfizer Inc

11.10.1. Company Overview

11.10.2. Disorder Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. MEDA Pharma GmBH & Co. KG

11.11.1. Company Overview

11.11.2. Disorder Overview

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. Others

12. APPENDIX

12.1. References

12.2. Related Reports 

LIST OF TABLES

TABLE 1 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SYNOPSIS, 2023-2030

TABLE 2 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET ESTIMATES & FORECAST, 2023-2030(USD Billion)

TABLE 3 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2023-2030(USD Billion)

TABLE 4 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030(USD Billion)

TABLE 5 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030(USD Billion)

TABLE 6 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY REGION, 2023-2030(USD Billion)

TABLE 7 NORTH AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2023-2030(USD Billion)

TABLE 8 NORTH AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030(USD Billion)

TABLE 9 NORTH AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030(USD Billion)

TABLE 10 US: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2023-2030(USD Billion)

TABLE 11 US: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030(USD Billion)

TABLE 12 US: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030(USD Billion)

TABLE 13 CANADA: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2023-2030(USD Billion)

TABLE 14 CANADA: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030(USD Billion)

TABLE 15 CANADA: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030(USD Billion)

TABLE 16 LATIN AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2023-2030(USD Billion)

TABLE 17 LATIN AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030(USD Billion)

TABLE 18 LATIN AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030(USD Billion)

TABLE 19 EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2023-2030(USD Billion)

TABLE 20 EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030(USD Billion)

TABLE 21 EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030(USD Billion)

TABLE 22 WESTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2023-2030(USD Billion)

TABLE 23 WESTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030(USD Billion)

TABLE 24 WESTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030(USD Billion)

TABLE 25 EASTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2023-2030(USD Billion)

TABLE 26 EASTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030(USD Billion)

TABLE 27 EASTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030(USD Billion)

TABLE 28 ASIA-PACIFIC: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2023-2030(USD Billion)

TABLE 29 ASIA-PACIFIC: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030(USD Billion)

TABLE 30 ASIA-PACIFIC: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030(USD Billion)

TABLE 31 MIDDLE EAST & AFRICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2023-2030(USD Billion)

TABLE 32 MIDDLE EAST & AFRICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2023-2030(USD Billion)

TABLE 33 MIDDLE EAST & AFRICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2023-2030(USD Billion)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET

FIGURE 4 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY DISORDER, 2023 (%)

FIGURE 5 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY TREATMENT, 2023 (%)

FIGURE 6 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY END USER, 2023 (%)

FIGURE 7 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY REGION, 2023 (%)

FIGURE 7 AMERICAS: DIABETIC NEUROPATHY TREATMENT MARKET SHARE BY REGION, 2023 (%)

FIGURE 8 NORTH AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 9 EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY REGION, 2023 (%)

FIGURE 10 WESTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 11 ASIA-PACIFIC: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 12 MIDDLE EAST & AFRICA: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 13 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 14 ABBOTT LABORATORIES.: KEY FINANCIALS

FIGURE 15 ABBOTT LABORATORIES: SEGMENTAL REVENUE

FIGURE 16 ABBOTT LABORATORIES: REGIONAL REVENUE

FIGURE 17 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

FIGURE 18 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 19 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 20 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 21 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 22 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 23 JOHNSON & JOHNSON: KEY FINANCIALS

FIGURE 24 JOHNSON & JOHNSON: SEGMENTAL REVENUE

FIGURE 25 JOHNSON & JOHNSON: REGIONAL REVENUE

FIGURE 26 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 27 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 28 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 29 LUPIN LIMITED: KEY FINANCIALS

FIGURE 30 LUPIN LIMITED: SEGMENTAL REVENUE

FIGURE 31 LUPIN LIMITED: REGIONAL REVENUE

FIGURE 32 GLENMARK PHARMACEUTICALS LIMITED: KEY FINANCIALS

FIGURE 33 GLENMARK PHARMACEUTICALS LIMITED: SEGMENTAL REVENUE

FIGURE 34 GLENMARK PHARMACEUTICALS LIMITED: REGIONAL REVENUE

FIGURE 35 DEPOMED, INC: KEY FINANCIALS

FIGURE 36 DEPOMED, INC: SEGMENTAL REVENUE

FIGURE 37 DEPOMED, INC: REGIONAL REVENUE

FIGURE 38 ASTELLAS PHARMA INC: KEY FINANCIALS

FIGURE 39 ASTELLAS PHARMA INC: SEGMENTAL REVENUE

FIGURE 40 ASTELLAS PHARMA INC: REGIONAL REVENUE

FIGURE 41 PFIZER INC: KEY FINANCIALS

FIGURE 42 PFIZER INC: SEGMENTAL REVENUE

FIGURE 43 PFIZER INC: REGIONAL REVENUE

FIGURE 44 MEDA PHARMA GMBH & CO. KG: KEY FINANCIALS

FIGURE 45 MEDA PHARMA GMBH & CO. KG: SEGMENTAL REVENUE

FIGURE 46 MEDA PHARMA GMBH & CO. KG: REGIONAL REVENUE